Web Results

en.wikipedia.org/wiki/Bruesewitz_v._Wyeth

Bruesewitz v. Wyeth, 562 U.S. 223 (2011), is a United States Supreme Court case that decided whether a section of the National Childhood Vaccine Injury Act of 1986 preempts all vaccine design defect claims against vaccine manufacturers . Contents. [hide]. 1 Background; 2 Decision; 3 See also; 4 References; 5 External ...

caselaw.findlaw.com/us-supreme-court/09-152.html

United States Supreme Court. BRUESEWITZ ET AL. v. WYETH LLC, FKA WYETH, INC., ET AL., (2011). No. 09-152. Argued: October 12, 2010 Decided: February 22, 2011. The National Childhood Vaccine Injury Act of 1986 (NCVIA or Act) created a no-fault compensation program to stabilize a vaccine market adversely ...

www.courtswv.gov/supreme-court/docs/fall2010/35296.htm

Wyeth & Ketchum W. Henry Jernigan Michael J. Farrell Dinsmore & Shohl Erik W. Legg Charleston, West Virginia Farrell, Farrell & Farrell Counsel for Amicus, Huntington, West Virginia Product Liabililty Council Anthony Majestro Jill Miles Charleston, West Virginia Assistant Attorney General Counsel for Amicus, Counsel for ...

biotech.law.lsu.edu/cases/drugs/perez_v_wyeth_laboratories_inc.htm

Wyeth Laboratories Inc., 161 N.J. 1, 734 A.2d 1245 (N.J. 1999). Guide - Perez v. Wyeth Laboratories Inc., 161 N.J. 1, 734 A.2d 1245 (N.J. Aug 09, 1999). [ footnotes have been ..... Charles J. Walsh et al., The Learned Intermediary Doctrine: The Correct Prescription for Drug Labeling, 48 Rutgers L. Rev. 821, 869 (1994). Thus ...

www.justice4all.org/wp-content/uploads/2017/09/States-Response-in-opposition-to-Motion-for-Judicial-Notice.pdf

DAMIAN STINNIE, et al.,. Plaintiffs-Appellants, v. RICHARD HOLCOMB, in his official capacity as Commissioner of the Virginia Department of Motor Vehicles, .... [Local Rule 28(b)] attachments were not submitted to the district court, we have not considered them in resolving this appeal.”); Rohrbough v. Wyeth Labs., Inc.,.

juryverdicts.net/tersignidefensebrief.pdf

Mar 6, 2012 ... v. WYETH LLC f/k/a AMERICAN HOME. PRODUCTS CORPORATION, et al.,. Defendants. CIVIL ACTION. No. 1:11-cv-10466-RGS. DEFENDANTS' ... Rich,. Features of PHT at 147-48; see also Dr. Waxman Dep. at 26:18-27:11 (Ex. D). In this case, Plaintiff claims to have PAH – one of five recognized types ...

www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)90250-7/fulltext

Sep 25, 1999 ... However, the gap between vaccines available for children in rich and in poor regions is widening. ... A trial of the Wyeth-Lederle heptavalent CRM197 conjugate vaccine in 37 000 Californian children immunised at 2, 4, 6, and 12-15 months of age, showed ..... 20Perez-Schael, I, Guntinas, MJ, Perez, M et al.

www.nejm.org/doi/full/10.1056/NEJMp1000938

May 27, 2010 ... Recently, the U.S. Supreme Court agreed to review a case, Bruesewitz v. Wyeth, in which the U.S. Court of Appeals for the Third Circuit held that NCVIA bars a state-law design-defect claim brought by a minor after the Vaccine Court found that the whole-cell diphtheria–pertussis–tetanus vaccine did not ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2700833

May 9, 2009 ... Inhibition of endosomal acidification by a specific inhibitor of the vacuolar H+- ATPase, bafilomycin A1, reduces luc expression by WR (Townsley et al., 2006). Bafilomycin A1 reduced entry of WR (Fig. 2A) and Wyeth (Fig 2D) strains by about 50% at neutral pH in BS-C-1 cells, but had little or no effect on ...